Nanoscale Enzyme Therapy - News Item

An Israeli subsidiary to BioDelivery Sciences International Inc. (BDSI) is being created to develop nanoscale drug-delivery therapies to treat an inherited disease caused by an enzyme deficiency. Tentatively called Biorazyme Ltd., the company is co-owned by Newark, N.J. based BDSI and Israeli joint venture partners. It will develop a new oral enzyme replacement for Gaucher Disease.

BDSI's Bioral delivery technology uses nanocrystalline delivery vehicles made from all-natural components that wrap around the enzyme and allow it to be delivered into the body. 

Posted 25th November 2003

Tell Us What You Think

Do you have a review, update or anything you would like to add to this article?

Leave your feedback
(Logout)
Submit

Characterization Techniques of PAC-G

In this interview, AZoM talks to Rafael Varela Della Giustina, Business developer at PAC-G, about the capabilities of PAC-G, and who it would serve best.

Characterization Techniques of PAC-G

Newsletters you may be interested in

See all Newsletters »